Other formats:
BibTeX
LaTeX
RIS
@article{2387657,
author = {Žáčková, Daniela and Semerád, Lukáš and Faber, Edgar and Klamová, Hana and Stejskal, Lukáš and Bělohlávková, Petra and Karas, Michal and Cmunt, Eduard and Černá, Olga and Procházková, Jiřina and Čičátková, Petra and Kvetková, Anežka and Horňák, Tomáš and Skoumalová, Ivana and Srbová, Dana and Šálek, Cyril and Buffa, David and Voglová, Jaroslava and Jurček, Tomáš and Folta, Adam and Ježíšková, Ivana and Žižková, Hana and Machová Poláková, Kateřina and Papajík, Tomáš and Žák, Pavel and Jindra, Pavel and Svobodník, Adam and Štěpánová, Radka and Mayer, Jiří},
article_location = {LONDON},
doi = {http://dx.doi.org/10.1038/s41375-024-02215-9},
language = {eng},
issn = {0887-6924},
journal = {Leukemia},
title = {Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF},
url = {https://www.nature.com/articles/s41375-024-02215-9},
year = {2024}
}
TY - JOUR
ID - 2387657
AU - Žáčková, Daniela - Semerád, Lukáš - Faber, Edgar - Klamová, Hana - Stejskal, Lukáš - Bělohlávková, Petra - Karas, Michal - Cmunt, Eduard - Černá, Olga - Procházková, Jiřina - Čičátková, Petra - Kvetková, Anežka - Horňák, Tomáš - Skoumalová, Ivana - Srbová, Dana - Šálek, Cyril - Buffa, David - Voglová, Jaroslava - Jurček, Tomáš - Folta, Adam - Ježíšková, Ivana - Žižková, Hana - Machová Poláková, Kateřina - Papajík, Tomáš - Žák, Pavel - Jindra, Pavel - Svobodník, Adam - Štěpánová, Radka - Mayer, Jiří
PY - 2024
TI - Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF
JF - Leukemia
PB - SPRINGERNATURE
SN - 08876924
UR - https://www.nature.com/articles/s41375-024-02215-9
N2 - Tyrosine kinase inhibitor (TKI) therapy discontinuation with the aim of achieving treatment-free remission (TFR) is becoming more frequent, as an increasing number of chronic myeloid leukemia (CML) patients are achieving stable deep molecular response (DMR; i.e. BCR::ABL1 transcript level ≤0.01% on the International Scale); however, many challenges remain unresolved. Among others, a nonnegligible proportion of patients reported fear, anxiety, or depression both during TFR and when they had to reinitiate TKI therapy. Similar negative feelings are frequently mentioned in the context of the decision to not stop TKI treatment; furthermore, a considerable proportion of patients (17–50%) have been reported to be unwilling to attempt TFR. However, little is known about how many truly eligible patients are unwilling to attempt TFR, the reasons for their decision and what factors are associated with their unwillingness to discontinue long-term therapy since the reports mentioned above have substantial limitations. The surveys were often conducted in a limited number of centres, focused on patients who are able to use internet tools, focused on more educated patients who are connected to patient supportive organisations, and usually not specifically focused on patients who fulfilled the criteria for TKI discontinuation.
ER -
ŽÁČKOVÁ, Daniela, Lukáš SEMERÁD, Edgar FABER, Hana KLAMOVÁ, Lukáš STEJSKAL, Petra BĚLOHLÁVKOVÁ, Michal KARAS, Eduard CMUNT, Olga ČERNÁ, Jiřina PROCHÁZKOVÁ, Petra ČIČÁTKOVÁ, Anežka KVETKOVÁ, Tomáš HORŇÁK, Ivana SKOUMALOVÁ, Dana SRBOVÁ, Cyril ŠÁLEK, David BUFFA, Jaroslava VOGLOVÁ, Tomáš JURČEK, Adam FOLTA, Ivana JEŽÍŠKOVÁ, Hana ŽIŽKOVÁ, Kateřina MACHOVÁ POLÁKOVÁ, Tomáš PAPAJÍK, Pavel ŽÁK, Pavel JINDRA, Adam SVOBODNÍK, Radka ŠTĚPÁNOVÁ and Jiří MAYER. Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF. \textit{Leukemia}. LONDON: SPRINGERNATURE, 2024. ISSN~0887-6924. Available from: https://dx.doi.org/10.1038/s41375-024-02215-9.
|
